Who are the top shareholders of the Eiko Lifescience?

The top shareholders of Eiko Lifescience are Lenus Finvest Private Limited with 17.01%, followed by 2b Black Bio LLP at 9.95%, while individual investors hold 44.38%. There are no institutional holdings or pledged promoter shares.

The top shareholders of Eiko Lifescience include Lenus Finvest Private Limited, which holds the highest promoter stake at 17.01%. The highest public shareholder is 2b Black Bio LLP, with a holding of 9.95%. Additionally, individual investors collectively own 44.38% of the company. There are currently no institutional holdings or pledged promoter shares.

Has Eiko Lifescience declared dividend?

Eiko Lifesciences Ltd has declared a 2% dividend, amounting to 0.2 per share, but the dividend yield is 0%. Total returns have varied significantly, with a notable 252.7% increase over the 5-year period, despite negative returns in shorter time frames.

Eiko Lifesciences Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: 0.2<BR>- Ex-date: 20 Sep 17<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -21.94%, the dividend return was 0%, resulting in a total return of -21.94%.<BR><BR>For the 1-year period, the price return was 2.51%, the dividend return was 0%, leading to a total return of 2.51%.<BR><BR>Over the 2-year period, the price return was -26.43%, with a dividend return of 0%, resulting in a total return of -26.43%.<BR><BR>In the 3-year period, the price return was -8.45%, the dividend return was 0%, giving a total return of -8.45%.<BR><BR>For the 4-year period, the price return was -34.26%, with a dividend return of 0%, leading to a total return of -34.26%.<BR><BR>In the 5-year period, the price return was 252.7%, the dividend return was 0%, resulting in a total return of 252.7%.<BR><BR>Overall, Eiko Lifesciences Ltd has declared a dividend, but the dividend yield remains at 0%, indicating that the dividends have not contributed to returns in recent periods. The total returns over various periods show significant fluctuations, with a notable increase over the 5-year period despite negative returns in shorter time frames.

Who are the peers of the Eiko Lifescience?

Eiko Lifescience's peers include Pidilite Inds., SRF, Gujarat Fluoroch, and others. Eiko has below average management risk and a 1-year return of 2.43%, lower than SRF's 30.72% but higher than Deepak Nitrite's -9.57%.

Peers: The peers of Eiko Lifescience are Pidilite Inds., SRF, Gujarat Fluoroch, Deepak Nitrite, Himadri Special, Crestchem, Hardcast.& Waud, Seya Industries, Yug Decor, and Vikram Aroma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Pidilite Inds., SRF, and Crestchem, while Good management risk is found at Himadri Special and Yug Decor. Average management risk is noted at Gujarat Fluoroch, while Below Average management risk is present at Eiko Lifescience, Hardcast.& Waud, Seya Industries, and Vikram Aroma. Growth is Good at Eiko Lifescience, Himadri Special, and Crestchem, while Average growth is seen at Pidilite Inds. and SRF. Below Average growth is noted at Gujarat Fluoroch, Deepak Nitrite, Hardcast.& Waud, Seya Industries, and Vikram Aroma. Capital Structure is Excellent at Pidilite Inds., Deepak Nitrite, and Eiko Lifescience, Good at Gujarat Fluoroch, Himadri Special, Crestchem, and Hardcast.& Waud, while Below Average is found at Seya Industries.<BR><BR>Return Snapshot: The peer with the highest 1-year return is SRF at 30.72%, while the peer with the lowest is Deepak Nitrite at -9.57%. Eiko Lifescience's 1-year return is 2.43%, which is lower than SRF's but higher than Deepak Nitrite's. Additionally, the peers with negative six-month returns include Deepak Nitrite, Crestchem, Seya Industries, and Vikram Aroma.

What is the technical trend for Eiko Lifescience?

As of May 23, 2025, Eiko Lifescience's technical trend is mildly bearish, with bearish signals from moving averages and Bollinger Bands, although the weekly MACD and KST indicate some mildly bullish momentum.

As of 23 May 2025, the technical trend for Eiko Lifescience has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands are bearish on both weekly and monthly time frames, and daily moving averages also reflect a bearish trend. The KST shows a mildly bullish signal on both weekly and monthly charts, and Dow Theory suggests a mildly bullish outlook on the weekly basis but no trend on the monthly. Overall, the current technical stance is mildly bearish, influenced primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish signals from MACD and KST on the weekly time frame.

Who are in the management team of Eiko Lifescience?

As of March 2022, the management team of Eiko Lifescience includes Laxmikant Kabra (Chairman), Bhavesh Dhirajlal Tanna, Rajkumar K Baheti, Mandkar Kamalakar Patil, Kajal Dhanpatraj Kothari (all Independent Non-Executive Directors), Umesh Ravindranath More (Whole-time Director), and Chintan Doshi (Company Secretary & Compliance Officer). Each member contributes to the company's governance structure.

As of March 2022, the management team of Eiko Lifescience includes the following individuals:<BR><BR>1. Laxmikant Kabra - Chairman & Non Executive Director<BR>2. Bhavesh Dhirajlal Tanna - Non-Executive & Non-Independent Director<BR>3. Rajkumar K Baheti - Independent Non-Executive Director<BR>4. Mandkar Kamalakar Patil - Independent Non-Executive Director<BR>5. Kajal Dhanpatraj Kothari - Independent Non-Executive Director<BR>6. Umesh Ravindranath More - Whole-time Director<BR>7. Chintan Doshi - Company Secretary & Compliance Officer<BR><BR>Each member plays a distinct role within the company's governance structure.

What does Eiko Lifescience do?

Eiko Lifesciences Ltd is a manufacturer and exporter of Specialty Chemicals and Pharma Intermediates, originally incorporated in 1977 and rebranded in 2021. As of March 2025, it reported net sales of 113 Cr and a net profit of 10 Cr, with a market cap of INR 74 Cr.

Overview: <BR>Eiko Lifesciences Ltd is a leading manufacturer, supplier, and exporter of Specialty Chemicals and Pharma Intermediates, operating within the Specialty Chemicals industry and classified as a Micro Cap company.<BR><BR>History: <BR>Eiko Lifesciences Ltd was originally incorporated on January 07, 1977, under the name Narendra Investments (Delhi) Limited. The company changed its name to Eiko Lifesciences Limited effective from June 24, 2021. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 113 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 10 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 74 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 50.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.03 <BR>Return on Equity: 2.63% <BR>Price to Book: 1.31 <BR><BR>Contact Details: <BR>Address: 1st Matru Chhaya Ground Floor, M Karve Road Naupada Thane Maharashtra : 400602 <BR>Tel: 91-22-25390009/25438095 <BR>Email: narendrainvestmentdelhi@gmail.com <BR>Website: http://www.eikolifesciences.com

How big is Eiko Lifescience?

As of 24th July, Eiko Lifesciences Ltd has a market capitalization of 74.00 Cr, with net sales of 37.67 Cr and a net profit of 2.11 Cr reported in the latest four quarters.

As of 24th July, Eiko Lifesciences Ltd has a market capitalization of 74.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Eiko Lifesciences reported net sales of 37.67 Cr and a net profit of 2.11 Cr.<BR><BR>The latest annual period for the balance sheet is March 2020, with shareholder's funds amounting to 2.95 Cr and total assets of 10.42 Cr.

When is the next results date for Eiko Lifescience?

Eiko Lifescience will announce its results on 29 July 2025.

Eiko Lifescience is scheduled to declare its results on 29 July 2025.

Are Eiko Lifescience latest results good or bad?

Eiko Lifesciences' latest results show strong revenue growth of 43.01% and a net profit increase of 285.71%, but a low return on equity of 3.23% raises concerns about capital efficiency and long-term profitability. Investors should approach with caution despite the positive revenue trends.

Eiko Lifesciences' latest results present a mixed picture. On one hand, the company has achieved impressive revenue growth, with net sales increasing by 43.01% year-on-year to ₹11.67 crores in Q2 FY2026. Additionally, net profit has surged by 285.71% year-on-year to ₹1.08 crores, reflecting a strong upward trend in profitability. The operating margin has also reached a record high of 15.17%, indicating improved operational efficiency.<BR><BR>However, despite these positive indicators, there are significant concerns regarding the company's capital efficiency. The return on equity (ROE) stands at a low 3.23%, which is well below industry standards and suggests that the company is not effectively generating returns from its equity. This weak ROE, combined with the absence of institutional interest and the company's relatively small operational scale, raises red flags about its long-term profitability potential.<BR><BR>In summary, while Eiko Lifesciences shows strong revenue growth and margin improvements, the underlying issues with capital efficiency and profitability metrics suggest caution for investors.

Is Eiko Lifescience overvalued or undervalued?

As of November 13, 2025, Eiko Lifescience is considered undervalued with an attractive valuation grade, featuring a PE ratio of 31.29, an EV to EBITDA of 30.99, and a PEG ratio of 0.32, which positions it favorably compared to peers like Bajaj Finance and Bajaj Finserv, despite recent underperformance against the Sensex.

As of 13 November 2025, Eiko Lifescience's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued. Key ratios include a PE ratio of 31.29, an EV to EBITDA of 30.99, and a PEG ratio of 0.32, which suggests that the stock is relatively inexpensive compared to its growth prospects.<BR><BR>In comparison to its peers, Eiko Lifescience's PE ratio is lower than Bajaj Finance's 34.18 and significantly better than the life insurance sector's 11.18, which is categorized as very attractive. Additionally, while Bajaj Finserv is considered expensive with a PE of 33.91, Eiko's valuation appears more favorable. Despite recent underperformance against the Sensex, particularly in the year-to-date and one-year returns, the company's attractive valuation metrics suggest potential for future growth.

How has been the historical performance of Eiko Lifescience?

Eiko Lifescience has shown significant growth from March 2018 to March 2025, with net sales rising from 2.34 crore to 37.66 crore and profit after tax increasing from 0.20 crore to 2.18 crore, alongside a substantial rise in total assets. The company has improved operational efficiency, reflected in higher operating profit and earnings per share.

Answer:<BR>The historical performance of Eiko Lifescience shows significant growth in net sales and profitability over the years, particularly from March 2018 to March 2025.<BR><BR>Breakdown:<BR>Eiko Lifescience's net sales increased dramatically from 2.34 crore in March 2018 to 37.66 crore in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 2.34 crore to 37.66 crore during the same period. The company's total expenditure also grew, from 1.99 crore in March 2018 to 34.90 crore in March 2025, but the operating profit (PBDIT) improved from 0.41 crore to 3.48 crore, indicating enhanced operational efficiency. Profit before tax transitioned from a profit of 0.25 crore in March 2018 to a profit of 2.92 crore in March 2025, while profit after tax showed a similar positive trend, moving from 0.20 crore to 2.18 crore. The earnings per share (EPS) improved significantly from 0.51 in March 2018 to 1.53 in March 2025. On the balance sheet, total assets increased from 10.95 crore in March 2018 to 66.10 crore in March 2025, with total liabilities also rising from 10.95 crore to 66.10 crore. The company reported a net cash outflow of 1.00 crore in March 2025, with closing cash and cash equivalents at 11.00 crore, up from virtually none in previous years. Overall, Eiko Lifescience has demonstrated substantial growth in both revenue and profitability, alongside an increase in assets and liabilities over the years.

Should I buy, sell or hold Eiko Lifescience?

Which are the latest news on Eiko Lifescience?

Why is Eiko Lifescience falling/rising?

As of 03-Dec, Eiko Lifesciences Ltd's stock price is currently at 51.95, reflecting a short-term gain despite a year-to-date decline of 17.20%. The stock has outperformed its sector recently, but reduced investor participation suggests potential challenges ahead.

As of 03-Dec, Eiko Lifesciences Ltd's stock price is rising, currently at 51.95, reflecting a change of 0.75 (1.46%) upwards. This increase is notable as the stock has outperformed its sector by 2.52% today and has been on a consecutive gain for the last two days, accumulating a total return of 1.98% during this period. <BR><BR>Despite the positive movement today, it is important to note that the stock has experienced a decline over longer periods, with a year-to-date decrease of 17.20% and a one-year decline of 13.98%. However, in the short term, the stock is performing better than the benchmark Sensex, which has seen a decline of 0.59% over the past week. <BR><BR>The stock's current price is higher than its 5-day moving average, although it remains lower than the 20-day, 50-day, 100-day, and 200-day moving averages. This suggests that while there is some upward momentum, it may not be strong enough to indicate a sustained recovery. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 42.05% compared to the 5-day average, which could indicate a lack of confidence among investors despite the recent price increase. <BR><BR>Overall, the stock's rise today can be attributed to short-term performance improvements and sector outperformance, but it faces challenges from longer-term declines and reduced investor engagement.